VanEck Associates’s Haemonetics HAE Stock Holding History

VanEck Associates’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43,854	Closed	-$2.79M	–	1421
2025 Q1	$2.79M	Buy	43,854 +4,234	+11%	+$288K	﹤0.01%	902
2024 Q4	$3.09M	Buy	+39,620	New	+$3.18M	﹤0.01%	860
2021 Q2	–	Sell	-254	Closed	-$28K	–	1296
2021 Q1	$28K	Buy	+254	New	+$31.4K	﹤0.01%	1144

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VanEck Associates's HAE Position: Q2 2025 in Review

VanEck Associates sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 43,854 shares — an estimated $2.79M sold.

VanEck Associates first reported a position in HAE in Q1 2021 and held it in 3 quarters. The position peaked at $3.09M in Q4 2024. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

VanEck Associates reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
VanEck Associates sold 43,854 Haemonetics shares in Q2 2025, an estimated $2.79M.
VanEck Associates first reported a position in Haemonetics in Q1 2021 and held it in 3 quarters.
VanEck Associates's Haemonetics position peaked at $3.09M in Q4 2024.
298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on VanEck Associates's 13F filing for Q2 2025, filed 14 Aug 2025.